Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Mona Hegazy

Mona Hegazy

Cairo university,Egypt

Title: NAFLD the coming global epidemic and health crisis, Egypt on the map

Biography

Biography: Mona Hegazy

Abstract

The ancient Egyptians were black Africans, displaced by later movements of peoples, for example the Macedonian, Roman and Arab. Arab invasion, do not seem to account more than15% of modern Egyptians. Because the epidemiology and demographic characteristics of NAFLD vary worldwide, we aimed to identify the risk factors of NAFLD among Egyptians. We had conducted a lot of researches regarding genetic polymorphism of the following: TNF-∂ G238A, PNPLA3, PPAR-gamma, Resistein  & Adiponectin receptors gene liver expression. Also we had worked on insulin resistance in non-diabetic patients with NAFLD, Total lipid profile, conjugated linolenic acid (omega 6), and intestinal microbiota. Our results showed that; Egyptian with different grads of NAFLD identified by NAS score in liver biopsy had significant TNF-∂ G238A, PNPLA3 polymorphism, and Resistein receptors gene liver expression in NASH patients.

In Egypt a high BMI and insulin resistance level in non-diabetic patients with NAFLD, and NASH even highest worldwide. Triglycerides was significantly high, HDL-c  was  low  in NASH patients, and we had low level of conjugated linolenic acid in NAFLD patients getting more worse with the severity of the disease. CD163, and LPS were significantly higher in patients with NASH prove the relation of intestinal dyspiosis and NASH. Egyptians had many genetic polymorphism related to NAFLD incidence and disease severity, in Egyptian obesity, and highest insulin resistance as main risk factors for NAFLD even in non-diabetics, and deficient conjugated linolenic acid had a role in  NASH progression, also modification of intestinal microbiota is a must to improve NAFLD.